24 August 2020>: Lab/In Vitro Research
Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells
Jiansheng Zhong 1ABE* , Jinli Zhang 2AB , Xiaoyang Yu 3BF , Xing Zhang 1CD , Linping Dian 1CDDOI: 10.12659/MSM.924922
Med Sci Monit 2020; 26:e924922
Figure 2 The cytotoxicity of olmutinib on K562 and K562/ADR cells overexpressing ETS1. (A) Representative immunoblot analysis together with relative protein expression of ETS1 in K562 cells (n=3). (B) Representative immunoblot analysis together with relative protein expression of ETS1 in K562/ADR cells (n=3). (C) Relative mRNA of ETS1 in K562 and K562/ADR cells, respectively (n=3). *** P<0.001 vs. Oe-NC group. (D) The effect of different concentrations of olmutinib on cell viability of K562 or K562/ADR cells transfected without (control) or with indicated vectors (n=3). * P, # P and & P<0.05 vs. 100%; ** P, ## P and && P<0.01 vs. 100%; *** P, ### P and &&& P<0.001 vs. 100%. Oe-NC – overexpression-negative control; Oe-ETS1 – overexpression-ETS1.